SLC5A2 and diabetes mellitus: Clinical trials have shown that the new therapies of sodium glucose cotransporter-2 (SGLT-2) inhibitors and glucagon like peptide-1 receptor agonists (GLP-1RA) to improve cardiorenal outcomes and their actions extend to include older people with diabetes [4].